Abstract
A new macrolide oral antibacterial agent, azithromycin (AZM), was used in 7 cases of respiratory infection to examine its clinical effectiveness. The drug was administered at a dose of 250 or 500mg once a day for 2 days in 1 case or 3 days in the remaining 6 cases. The results were assessed to be excellent in 1, good in 4 and undetermined in 2 cases. A possible pathogenic strain of Staphylococcus aureus was isolated, which was ultimately eradicated after the administration of AZM.
Mild nausea and slightly elevated GOT and GPT were noted as adverse reactions in 1 case each, but presented no problem clinically.
